Related references
Note: Only part of the references are listed.Respiratory Trajectories in Type 2 and 3 Spinal Muscular Atrophy in the iSMAC Cohort Study
Federica Trucco et al.
NEUROLOGY (2021)
Natural history of Type 2 and 3 spinal muscular atrophy: 2-year NatHis-SMA study
Melanie Annoussamy et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2021)
Understanding European patient expectations towards current therapeutic development in spinal muscular atrophy
Nicole Gusset et al.
NEUROMUSCULAR DISORDERS (2021)
Natural history of lung function in spinal muscular atrophy
Camiel A. Wijngaarde et al.
ORPHANET JOURNAL OF RARE DISEASES (2020)
Muscle strength and motor function in adolescents and adults with spinal muscular atrophy
Camiel A. Wijngaarde et al.
NEUROLOGY (2020)
SUNFISH Part 1: 24-month safety and exploratory outcomes of risdiplam (RG7916) treatment in patients with Type 2 or 3 spinal muscular atrophy (SMA)
J. Day et al.
NEUROMUSCULAR DISORDERS (2020)
Assessment of the validity and reliability of the 32-item Motor Function Measure in individuals with Type 2 or non-ambulant Type 3 spinal muscular atrophy
Dylan Trundell et al.
PLOS ONE (2020)
Validity and Reliability of the 32-Item Motor Function Measure in 2-to 5-Year-Olds with Neuromuscular Disorders and 2-to 25-Year-Olds with Spinal Muscular Atrophy
Dylan Trundell et al.
NEUROLOGY AND THERAPY (2020)
Long-term progression in type II spinal muscular atrophy A retrospective observational study
Eugenio Mercuri et al.
NEUROLOGY (2019)
A phase 1 healthy male volunteer single escalating dose study of the pharmacokinetics and pharmacodynamics of risdiplam (RG7916, RO7034067), a SMN2 splicing modifier
Stefan Sturm et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2019)
Moving from significance to real-world meaning: methods for interpreting change in clinical outcome assessment scores
Cheryl D. Coon et al.
QUALITY OF LIFE RESEARCH (2018)
Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy
E. Mercuri et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Discovery of Risdiplam, a Selective Survival of Motor Neuron-2 (SMN2) Gene Splicing Modifier for the Treatment of Spinal Muscular Atrophy (SMA)
Hasane Ratni et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
The clinical landscape for SMA in a new therapeutic era
K. Talbot et al.
GENE THERAPY (2017)
Early pediatric formulation development with new chemical entities: Opportunities of e-tongue besides human taste assessment
Laura Isabell Immohr et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2017)
Transdiagnostic Clinical Global Impression Scoring for Routine Clinical Settings
Boadie W. Dunlop et al.
BEHAVIORAL SCIENCES (2017)
Diverse role of survival motor neuron protein
Ravindra N. Singh et al.
BIOCHIMICA ET BIOPHYSICA ACTA-GENE REGULATORY MECHANISMS (2017)
Patterns of disease progression in type 2 and 3 SMA: Implications for clinical trials
Eugenio Mercuri et al.
NEUROMUSCULAR DISORDERS (2016)
Responsiveness of the Motor Function Measure in Patients With Spinal Muscular Atrophy
Carole Vuillerot et al.
ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION (2013)
Observational Study of Spinal Muscular Atrophy Type 2 and 3 Functional Outcomes Over 1 Year
Petra Kaufmann et al.
ARCHIVES OF NEUROLOGY (2011)
A motor function measure scale for neuromuscular diseases.: Construction and validation study
C Bérard et al.
NEUROMUSCULAR DISORDERS (2005)
Share Paper
